{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:21:35Z","timestamp":1788812495168,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,2,22]],"date-time":"2005-02-22T00:00:00Z","timestamp":1109030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Seborrhoeic dermatitis is an inflammatory cutaneous disorder in which the colonization of the affected area by Malassezia has been proved to play a key role.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To perform a noncomparative open clinical study with oral itraconazole capsule (200\u00a0mg\/day\u00a0\u00d7\u00a07\u00a0days) and consecutive usage 200\u00a0mg\/day for the first 2\u00a0days of the following 2\u00a0months in patients with seborrhoeic dermatitis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Twenty\u2010nine patients were enrolled to determine the efficacy and safety of oral itraconazole. The patients were evaluated according to itching, burning, erythema, desquamation and seborrhoea, each scored on a 0\u20134 scale on days\u00a015 (T15), 30 (T30), 60 (T 60) and 90 (T90). Itraconazole capsule 100\u00a0mg was given twice a day for 1\u00a0week and then, after a 3\u2010week interval, patients used itraconazole capsule 200\u00a0mg\/day for the first 2\u00a0days of the following 2\u00a0months. The clinical response was graded as markedly effective, effective, moderate or ineffective.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A clinical improvement (evaluated as markedly effective or effective) was observed in 23 patients\u00a0(83%) at T15, 21\u00a0(76%) at T30, 20\u00a0(72%) at T60 and 17\u00a0(61%) at T90. At baseline, the mean\u00a0\u00b1\u00a0SD total clinical scores were 10.44\u00a0\u00b1\u00a02.45, 1.98\u00a0\u00b1\u00a00.5, 2.97\u00a0\u00b1\u00a01.12, 3.15\u00a0\u00b1\u00a01.74 and 3.30\u00a0\u00b1\u00a01.90 at T0, T15, T30, T60 and T90, respectively. Compared with baseline values, itraconazole capsule significantly reduced the mean\u00a0\u00b1\u00a0SD total score as well as individual erythema and desquamation (Wilcoxon's signed test\u2010two tailed) (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.0001). No drug\u2010related systemic adverse event was observed during the study.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Seborrhoeic dermatitis shows marked reduction in inflammation when treated with itraconazole. The anti\u2010inflammatory activity of oral itraconazole and efficacy on Malessezia suggests that itraconazole capsule will be first oral treatment option in future in severe seborrhoeic dermatitis.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2005.01090.x","type":"journal-article","created":{"date-parts":[[2005,3,4]],"date-time":"2005-03-04T15:24:36Z","timestamp":1109949876000},"page":"172-175","source":"Crossref","is-referenced-by-count":26,"title":["Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial"],"prefix":"10.1111","volume":"19","author":[{"given":"O","family":"Kose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Erbil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AR","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,2,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001020-00001"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04082.x"},{"key":"e_1_2_5_4_2","first-page":"1","article-title":"Seborrheic dermatitis and Pityrosporum ovale: cultural, immunological, and clinical studies","volume":"167","author":"Bergbrabt IM","year":"1991","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.1999.00089.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00309.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80305-8"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03294.x"},{"key":"e_1_2_5_9_2","first-page":"4","article-title":"Itraconazole for seborrheic dermatitis","volume":"7","author":"Gupta AK","year":"2002","journal-title":"Skin Ther Lett"},{"key":"e_1_2_5_10_2","first-page":"1026","article-title":"Treatment of seborrheic dermatitis with antifungal drugs","volume":"173","author":"Masataro H","year":"1995","journal-title":"J Clin Exp Med"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1985.tb02094.x"},{"key":"e_1_2_5_12_2","first-page":"1","article-title":"Itraconazole: new horizons","volume":"137","author":"Caputo R","year":"2002","journal-title":"G Ital Derm Venereol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2005.01090.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2005.01090.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T04:45:36Z","timestamp":1696999536000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2005.01090.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,22]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1468-3083.2005.01090.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2005.01090.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,22]]}}}